Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1766181 | 0.86 | PTGS1 (0.36) | PTGS1PTGS2 | |
| SCHEMBL6417719 | 0.85 | — | — | |
| SCHEMBL861358 | 0.84 | KMT2A (0.31) | PTGER2 | |
| SCHEMBL14348230 | 0.82 | CPB2 (0.33) | — | |
| SCHEMBL20661164 | 0.81 | PTGS1 (0.35) | PTGS1PTGS2 | |
| Bicarbonate SCHEMBL9228837 | 0.80 | HTR1A (0.34) | PTGS1PTGS2 | |
| SCHEMBL5664409 | 0.78 | HTR1A (0.37) | — | |
| SCHEMBL181056 | 0.78 | HTR1A (0.37) | — | |
| SCHEMBL19326880 | 0.75 | PTGS1 (0.32) | PTGS1PTGS2 | |
| SCHEMBL3800428 | 0.75 | PTGS1 (0.40) | PTGS1PTGS2PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | claimed |
| WO-2024145600-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-04 | — | — | WO | claimed |
| US-11944688-B2 | Biologically active compounds | SUTURA THERAPEUTICS LTD (GB) | 2024-04-02 | — | — | US | claimed |
| WO-2023220678-A1 | CROSS-LINKED TUMOR LYSATE SPHERICAL NUCLEIC ACIDS AS CANCER VACCINES | NORTHWESTERN UNIVERSITY (US) | 2023-11-16 | — | — | WO | claimed |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | claimed |
| WO-2023146293-A1 | IMMUNOCONJUGATE TARGETING C-KIT | 주식회사 노벨티노빌리티 | 2023-08-03 | — | — | WO | claimed |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | SUTURA THERAPEUTICS LTD (TC) | 2023-01-03 | — | — | US | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| EP-1525480-A1 | MULTIPLE HYBRID IMMUNOASSAY | I-STAT CORPORATION (US) | 2005-04-27 | — | — | EP | claimed |
| US-20040072743-A1 | Pharmaceutical composition of modified pna molecules | PANTHECO A/S (DK) | 2004-04-15 | — | — | US | claimed |
| WO-2004011947-A1 | MULTIPLE HYBRID IMMUNOASSAY | I-STAT CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-20040018577-A1 | Multiple hybrid immunoassay | ABBOTT POINT OF CARE INC. | 2004-01-29 | — | — | US | claimed |
| US-20030129642-A1 | Novel compositions and methods for inhibiting light-induced inactivation of biological reagents | BIOSITE DIAGNOSTICS, INC. | 2003-07-10 | — | — | US | claimed |
| US-6544797-B1 | Oxidation resistance; complexing | BIOSITE DIAGNOSTICS, INC. | 2003-04-08 | — | — | US | claimed |
| EP-1296718-A1 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | Pantheco A/S (DK) | 2003-04-02 | — | — | EP | claimed |
| WO-2001076636-A2 | PHARMACEUTICAL COMPOSITION OF MODIFIED PNA MOLECULES | PANTHECO A/S (DK) | 2001-10-18 | — | — | WO | claimed |
| EP-0972194-A2 | COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS | BIOSITE DIAGNOSTICS INC. (US) | 2000-01-19 | — | — | EP | claimed |
| WO-1998045705-A2 | COMPOSITIONS AND METHODS FOR INHIBITING LIGHT-INDUCED INACTIVATION OF BIOLOGICAL REAGENTS | BIOSITE DIAGNOSTICS INCORPORATED (US) | 1998-10-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | BPGM, TMPO, SLC7A1 | PTGS1 4511/4885PTGS2 4428/4885PTGER3 4437/4885 |
| US-11944688-B2 | Biologically active compounds | BPGM, PICALM, TMPO | PTGS1 4574/4885PTGS2 4400/4885PTGER3 4395/4885 |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | SIGLEC7, FUT5, FUT6 | PTGS1 3702/4885PTGS2 3230/4885PTGER3 4215/4885 |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | BPGM, PICALM, TMPO | PTGS1 4574/4885PTGS2 4400/4885PTGER3 4395/4885 |
| US-11725222-B2 | Cleavable nucleotide analogs and uses thereof | TYMP, DUT, NT5C3B | PTGS1 1127/4885PTGS2 1270/4885PTGER3 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.